Skip to content
Knowledge Hub

Bone Marrow vs MSC Treatment

Reviewed by a clinical expert Published: 19 Feb 2026 Last updated: 20 Feb 2026

Terminology confusion between hematopoietic stem cell transplantation and mesenchymal stromal cell (MSC) treatment is widespread, despite these representing fundamentally different therapeutic approaches. Stem cell transplantation involves hematopoietic stem cell replacement for severe blood- and immune disorders, while MSC treatment utilizes stromal cells for regenerative applications. Understanding these clinical distinctions is essential for appropriate patient counselling, treatment selection, and regulatory compliance.

 

Hematopoietic Stem Cell Transplantation: Established Clinical Practice

Hematopoietic stem cell transplantation represents a well-established treatment modality for hematologic malignancies and other non-malignant blood and immune disorders.1 This procedure involves infusion of donor or autologous hematopoietic stem cells to reconstitute the patient's hematopoietic system. Clinical indications include acute leukemias, lymphomas, multiple myeloma, and severe aplastic anemia.1

The procedure requires extensive conditioning regimens prior to stem cell transplantation, typically involving high-dose chemotherapy or total body irradiation to enable engraftment and provide an antitumor effect.1 Newer conditioning regimens may involve serotherapy or monoclonal antibodies. Patients undergo prolonged hospitalization with intensive supportive care during engraftment, which occurs over 2–4 weeks.2 Long-term complications include graft-versus-host disease in allogeneic transplants, infections and secondary malignancies.3 The procedure carries significant morbidity and mortality risks, with treatment-related mortality rates varying from 10–30% depending on disease, patient factors and donor compatibility.1

Mesenchymal Stromal Cell Treatment: Emerging Therapeutic Paradigm

MSC therapy represents a distinct therapeutic approach utilizing multipotent stromal cells for regenerative medicine applications. Unlike hematopoietic stem cell transplantation, MSC therapy does not require myeloablative conditioning or donor-patient matching. Bone-marrow (BM)-MSC have immunomodulatory properties and paracrine signaling capabilities that support tissue repair and reduce inflammation.4

Clinical trials have evaluated intravenous and local MSC administration across diverse conditions including cardiovascular disease,5 Alzheimer’s disease,6 graft-versus-host disease, Crohn's disease, and osteoarthritis.7 In a landmark early trial, Le Blanc et al. demonstrated the efficacy of intravenous bone marrow–derived mesenchymal stromal cell therapy for steroid-resistant acute graft-versus-host disease, reporting an overall response rate of 69% in a phase II multicenter study involving 55 patients.8 The treatment profile differs markedly from transplantation, with minimal adverse events and possible outpatient administration protocols, depending on disease indication.

Manufacturing requirements for therapeutic MSCs include GMP-grade production facilities with extensive quality control measures.9 Cell characterization must demonstrate trilineage differentiation potential, specific surface marker expression, and plastic adherence properties as defined by the International Society for Cellular Therapy criteria.10

Clinical and Regulatory Considerations

The regulatory pathways for hematopoietic stem cell transplantation and MSC therapy differ substantially. Transplantation procedures operate under established clinical protocols with decades of safety data, while the majority of MSC therapies require investigational new drug applications for clinical trial conduct. Healthcare providers must understand these regulatory distinctions when counseling patients.

Treatment selection depends on underlying pathophysiology rather than stem cell availability. Hematopoietic stem cell transplantation is a potentially curative transplantation procedure for a broad range of severe malignant and non-malignant hematological disorders, replacing the patient's blood-forming cells. MSC treatment targets inflammatory and degenerative processes through immunomodulation and tissue regenerative mechanisms, with hundreds of ongoing clinical trials currently evaluating its therapeutic applications across a broad range of diseases.11,12

Conclusion

Hematopoietic stem cell transplantation and MSC treatment represent distinct therapeutic modalities with different clinical applications, risk profiles, and regulatory requirements. Healthcare professionals must maintain clear conceptual separation between these approaches to ensure appropriate patient care and regulatory compliance. The expanding availability of GMP-grade BM-MSCs creates new opportunities for regenerative medicine applications while maintaining the established role of hematopoietic stem cell transplantation for hematologic disorders.

  1. Sureda, A., Corbacioglu, S., Greco, R., Kröger, N. & Carreras, E. The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies. (2024).
  2. Kenyon, M. & Babic, A. The European blood and marrow transplantation textbook for nurses: Under the auspices of EBMT. (Springer Nature, 2023).
  3. Styczyński, J. et al. Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. Bone marrow transplantation 55, 126–136 (2020).
  4. Le Blanc, K. & Mougiakakos, D. Multipotent mesenchymal stromal cells and the innate immune system. Nature Reviews Immunology 12, 383–396 (2012).
  5. Perin, E. C. et al. Randomized trial of targeted transendocardial mesenchymal precursor cell therapy in patients with heart failure. Journal of the American College of Cardiology 81, 849–863 (2023).
  6. Rash, B. G. et al. Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer’s disease: a randomized controlled phase 2a trial. Nature medicine, 1–10 (2025).
  7. Wang, Y., Yi, H. & Song, Y. The safety of MSC therapy over the past 15 years: a meta-analysis. Stem cell research & therapy 12, 1–15 (2021).
  8. Le Blanc, K. et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. The Lancet 371, 1579–1586 (2008).
  9. Sensebé, L., Bourin, P. & Tarte, K. Good manufacturing practices production of mesenchymal stem/stromal cells. Human gene therapy 22, 19–26 (2011).
  10. Dominici, M. et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8, 315–317 (2006).
  11. Krampera, M. & Le Blanc, K. Mesenchymal stromal cells: Putative microenvironmental modulators become cell therapy. Cell stem cell 28, 1708–1725 (2021).
  12. Clinicaltrials.gov, search term "mesenchymal stem cells": https://clinicaltrials.gov/search?intr=mesenchymal%20stem%20cells&aggFilters=status:rec%20act